Beta Bionics Reports Strong Q4 & Full Year 2025 Results, Guides for Continued Growth in 2026

summarizeSummary

Beta Bionics reported strong Q4 and full year 2025 financial results with significant revenue and customer growth, alongside positive revenue guidance for 2026, and a healthy cash balance.

check_boxKey Events

• Strong Revenue Growth Reported

  Net sales for Q4 2025 increased 57% to $32.1 million, and full year 2025 net sales grew 54% to $100.3 million, driven by both DME and PBP channels.

• Significant Customer Base Expansion

  The installed customer base surged 129% year-over-year to 35,011 users, with new patient starts increasing 37% in Q4 2025 and 52% for the full year.

• Positive 2026 Revenue Guidance

  The company introduced full year 2026 revenue guidance of $130 million to $135 million, indicating continued strong growth expectations.

• Healthy Cash Position

  Beta Bionics ended 2025 with $264.7 million in cash, cash equivalents, and investments, providing a strong financial foundation.

auto_awesomeAnalysis

Beta Bionics, Inc. announced robust financial results for the fourth quarter and full year 2025, demonstrating significant growth in net sales and its customer base. This performance is particularly notable following the FDA warning letter received on January 30, 2026, indicating the company's operational strength despite regulatory challenges. The company also provided optimistic revenue guidance for 2026, projecting continued strong growth. The healthy cash position at year-end provides a substantial runway for ongoing operations and R&D initiatives, including progress on its bihormonal system.